undamentalytics Newsletter
Sign in

Sol-gel Technologies Ltd. (SLGL) stock

Add to watchlist

Add holding +

NASDAQ: SLGL Nasdaq Pharmaceuticals Next results ~November 19, 2026

C+ Fundamentals grade

Sol-gel Technologies Ltd. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$45

Revenue-to-maturity model

Base case. Range ~$39–$53. Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Sol-gel Technologies Ltd. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling49 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds11 adding, 9 cuttingOf 3 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Sol-gel Technologies files

Where Sol-gel Technologies stands after its latest Filing

Revenue for the twelve months was $19m, up 68.0% on a year earlier, slower than the 642.5% growth a quarter earlier. That growth ranks 8 of 74 among the pharmaceuticals companies we cover. Free-cash-flow margin rose to 1.4% from -25.1% a year earlier. Operating margin narrowed to -38.9% from 9.5%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 2 financial-health checks. Our revenue-to-maturity model value is $43.86 a share, against a share price of $68.35.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 19, 2026 (estimated)

Sol-gel Technologies Ltd.'s trailing-twelve-month revenue grew 68.0% year on year, with a free-cash-flow margin of 1.4%. Where it stands out: stock pay as % of revenue of 0.4% ranks 3 of 69 pharmaceuticals companies we cover. Where it lags: change in growth rate of -574.4pp ranks 74 of 74 pharmaceuticals companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 68.0% (-574.4pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 68.0% over the last 12 months, against a median of 10.0% for pharmaceuticals companies we cover.
  • Margins widening. Operating margin is up 65.2 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Growth slowing. The growth rate is 574.4 points lower than a quarter earlier.
  • Loss-making. Operating margin is -38.9%: costs exceed revenue.
  • Volatile shares. Over the past year the shares showed annualised volatility of 83% and a beta of 0.8 against the S&P 500.
  • Heavily shorted. 12.9% of the shares available to trade are sold short (3.2 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share
-$1.13 against an average estimate of -$2.31: beat by 51.1%
Next report
November 19, 2026; average EPS estimate -$2.07

Sol-gel Technologies' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.9%
  • 1 week-5.7%
  • 1 month-8.8%
  • This year+55.9%
  • 1 year+90.4%
  • 5 years-27.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$19.4M
Operating margin
-38.9%
Net margin
-31.6%
EPS (TTM, diluted)
$-2.20

Growth

Revenue growth
+68.0%
Change in growth rate
−574.4 pts
Share count change
+0.0%

Cash

Free cash flow (TTM)
$275,000
FCF margin
1.4%
Stock pay % of revenue
0.4%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Sol-gel Technologies Ltd. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Sol-gel Technologies Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 8.1%: the 10-year Treasury yield (4.9%) plus a beta of 0.69 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$8.2 ~$8.1–$8.2 Left out: out of range vs price (0.12x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.3 ~$0.3–$0.8 Left out: out of range vs price (0.00x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$45 ~$39–$53 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$45 ~$39–$53 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Sol-gel Technologies Ltd. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20182019202020212022202320242025
Share price$60.20$171.50$97.90$74.00$45.60$11.05$9.30$42.14
Market value$108m$335m$221m$174m$105m$30m$26m$117m
+ Net debt (− = net cash)−$5m−$9m−$7m−$20m−$12m−$8m−$19m−$11m
Enterprise value$102m$326m$214m$154m$93m$22m$6m$106m
Multiples
Price / sales n/m14.6x25.2x5.6x27.2x19.3x2.2x6.1x
Price / earnings ———54.1x————
Price / free cash flow ———————n/m
EV / EBITDA ———40.1x————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 19, 2026, before the open. Analysts expect revenue of $150000 and EPS of −$2.07 (range −$3.01 to −$1.54) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$7.75 −254% $1m −95%
Next −$8.03 −4% $566670 −45%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −6.8% on 90 days ago. In the last 30 days, 0 analysts raised Sol-gel Technologies Ltd.'s forecast and 0 cut it.

Consensus EPS forecast Sol-gel Technologies Ltd., last 90 days
−$15.00 −$10.00 −$5.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$8.32 Current fiscal year, 60 days ago: −$8.32 Current fiscal year, 30 days ago: −$11.78 Current fiscal year, 7 days ago: −$8.73 Current fiscal year, Now: −$7.75 −$7.75 Next fiscal year, 90 days ago: −$8.14 Next fiscal year, 60 days ago: −$8.14 Next fiscal year, 30 days ago: −$8.37 Next fiscal year, 7 days ago: −$8.36 Next fiscal year, Now: −$8.03 −$8.03

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$8.32−$8.14
60 days ago −$8.32−$8.14
30 days ago −$11.78−$8.37
7 days ago −$8.73−$8.36
Now −$7.75−$8.03

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$2.31 −$1.13 +51.1%
Mar 2026 −$2.86 −$1.31 +54.2%
Dec 2025 $0.39 −$1.06 −371.8%
Sept 2025 −$2.09 −$2.13 −1.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202644
  2. Sep 202633
  3. Aug 202644
  4. Jul 202644

Counts of recommendations published by analysts covering Sol-gel Technologies Ltd., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
12.9%
of tradable shares
Days to cover
3.16
at average volume
Short interest, 1 month
+12%
to October 15, 2026
Held by institutions
44%
of shares
Held by insiders
59.7%
of shares
Employees
28
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
SLGL−24%−38%−76%−16%+353%+56%
Industry peers (median)−18%−52%−13%−2%+7%−14%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
SLGL25%33%33%50%58%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
SLGL−58%−50%−83%−76%−71%−40%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since February 1, 2018: 98% from December 31, 2019 to August 9, 2024. Getting back needed a 4586% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$30.64 – $97.97
From 52-week high
−32.9%
vs 50-day average
−4.5%
vs 200-day average
−11.3%
Volatility (1 year)
83%
Beta vs S&P 500
0.85

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Sol-gel Technologies Ltd. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Sol-gel Technologies Ltd.
$0 $10M $20M $30M $40M FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue (TTM), FY17 Q4: $174K Revenue (TTM), FY18 Q4: $129K Revenue (TTM), FY19 Q4: $22.9M Revenue (TTM), FY20 Q4: $8.8M Revenue (TTM), FY21 Q4: $31.3M Revenue (TTM), FY22 Q4: $3.9M Revenue (TTM), FY23 Q4: $1.6M Revenue (TTM), FY24 Q4: $11.5M Revenue (TTM), FY25 Q4: $19.4M $19.4M

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue (TTM)
FY17 Q4 $174K
FY18 Q4 $129K
FY19 Q4 $22.9M
FY20 Q4 $8.8M
FY21 Q4 $31.3M
FY22 Q4 $3.9M
FY23 Q4 $1.6M
FY24 Q4 $11.5M
FY25 Q4 $19.4M
Revenue growth, TTM YoY Sol-gel Technologies Ltd.
-5000% 0% 5000% 10000% 15000% 20000% FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 Revenue growth, TTM YoY, FY18 Q4: -25.9% Revenue growth, TTM YoY, FY19 Q4: 17655.0% Revenue growth, TTM YoY, FY20 Q4: -61.7% Revenue growth, TTM YoY, FY21 Q4: 256.5% Revenue growth, TTM YoY, FY22 Q4: -87.6% Revenue growth, TTM YoY, FY23 Q4: -60.0% Revenue growth, TTM YoY, FY24 Q4: 642.5% Revenue growth, TTM YoY, FY25 Q4: 68.0% 68.0%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue growth, TTM YoY
FY18 Q4 -25.9%
FY19 Q4 17655.0%
FY20 Q4 -61.7%
FY21 Q4 256.5%
FY22 Q4 -87.6%
FY23 Q4 -60.0%
FY24 Q4 642.5%
FY25 Q4 68.0%
Operating margin (TTM) Sol-gel Technologies Ltd.
-30000% -20000% -10000% 0% 10000% FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Operating margin (TTM), FY17 Q4: -18179.9% Operating margin (TTM), FY18 Q4: -25985.3% Operating margin (TTM), FY19 Q4: -113.3% Operating margin (TTM), FY20 Q4: -344.7% Operating margin (TTM), FY21 Q4: 9.5% Operating margin (TTM), FY22 Q4: -418.3% Operating margin (TTM), FY23 Q4: -1885.8% Operating margin (TTM), FY24 Q4: -104.1% Operating margin (TTM), FY25 Q4: -38.9% -38.9%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Operating margin (TTM)
FY17 Q4 -18179.9%
FY18 Q4 -25985.3%
FY19 Q4 -113.3%
FY20 Q4 -344.7%
FY21 Q4 9.5%
FY22 Q4 -418.3%
FY23 Q4 -1885.8%
FY24 Q4 -104.1%
FY25 Q4 -38.9%
FCF margin (TTM) Sol-gel Technologies Ltd.
-20000% -15000% -10000% -5000% 0% 5000% FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 FCF margin (TTM), FY17 Q4: -14950.6% FCF margin (TTM), FY18 Q4: -19007.0% FCF margin (TTM), FY19 Q4: -100.8% FCF margin (TTM), FY20 Q4: -292.9% FCF margin (TTM), FY21 Q4: -25.1% FCF margin (TTM), FY22 Q4: -248.6% FCF margin (TTM), FY23 Q4: -1149.5% FCF margin (TTM), FY24 Q4: -120.4% FCF margin (TTM), FY25 Q4: 1.4% 1.4%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period FCF margin (TTM)
FY17 Q4 -14950.6%
FY18 Q4 -19007.0%
FY19 Q4 -100.8%
FY20 Q4 -292.9%
FY21 Q4 -25.1%
FY22 Q4 -248.6%
FY23 Q4 -1149.5%
FY24 Q4 -120.4%
FY25 Q4 1.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F, 20-F/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 0 0 23 9 31 4 2 12 19
EBITDA −31 −33 −25 −29 4 −16 −29 −12 −7
Operating income −32 −34 −26 −30 3 −16 −29 −12 −8
Net income −32 −32 −25 −29 3 −15 −27 −11 −6
Diluted EPS $16.73 $18.00 −$12.60 −$13.00 $1.40 −$6.50 −$10.01 −$3.79 −$2.19
Growth (year on year)
Revenue — −25.9% +>999% −61.7% +256.5% −87.6% −60.0% +642.5% +68.0%
EBITDA — — — — — −508.0% — — —
Operating income — — — — — −648.0% — — —
Net income — — — — — −563.3% — — —
Diluted EPS — — — — — −564.3% — — —
Margins
EBITDA margin <−999% <−999% −109.4% −333.9% 12.3% −403.9% <−999% −102.1% −38.3%
Operating margin <−999% <−999% −113.3% −344.7% 9.5% −418.3% <−999% −104.1% −38.9%
Net margin <−999% <−999% −107.4% −333.9% 10.3% −384.3% <−999% −91.7% −31.6%
Free-cash-flow margin <−999% <−999% −100.8% −292.9% −25.1% −248.6% <−999% −120.4% 1.4%
Cash flow
Cash from operations −24 −23 −23 −25 −8 −9 −18 −14 0
Capital spending 2 1 1 0 0 0 0 0 0
Free cash flow −26 −25 −23 −26 −8 −10 −18 −14 0
Stock-based pay 4 5 3 1 1 2 2 1 0
Free cash flow after stock pay −30 −29 −26 −27 −9 −11 −20 −15 0
Balance sheet
Cash 5 5 9 7 20 12 8 19 11
Total debt 65 0 0 0 0 0 0 0 0
Net debt (negative = net cash) 60 −5 −9 −7 −20 −12 −8 −19 −11
Diluted shares 2m 2m 2m 2m 2m 2m 3m 3m 3m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · December 31, 2025
What it owns · $30m
Short-term assets $27mLonger-term assets $3m
What it owes, and who funded it · $30m
Short-term liabilities $6mLonger-term liabilities $1mShareholders' equity $23m
  • Short-term assets cover short-term liabilities $27m of assets due within a year against $6m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $27m short-term assets against $935,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Sol-gel Technologies Ltd.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+0.0%
year over year
R&D spending
117.6%
of revenue
Days sales outstanding
37 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated SLGL ZYBT JAGX VRCA SCLX SBFM Median
Revenue, last 12 months $19m $16m $28m $30m $32m $35m $276m
Revenue growth, last 12 months 68.0% −37.5% 135.5% 106.2% −28.5% −2.7% 9.9%
Revenue growth, 3-year average — — 76.5% 52.2% −12.0% 34.5% 5.5%
Revenue growth, latest quarter — — −58.9% −53.8% −22.8% −1.6% 6.5%
Gross margin — 20.5% 82.3% 63.8% 55.5% 30.3% 62.0%
Operating margin −38.9% −60.6% −93.1% −93.6% <−999% −16.6% −5.9%
Operating margin, 3-year average <−999% — −227.7% −312.8% −512.2% −16.5% −7.4%
Net margin −31.6% −60.0% −188.5% −102.8% <−999% −16.5% −7.3%
Cash from operations / revenue 1.7% 11.5% −24.0% −44.0% −54.1% −15.1% 10.2%
Free-cash-flow margin 1.4% 10.6% −24.0% −44.0% −70.7% −15.2% 8.6%
Free-cash-flow margin, 3-year average <−999% — −182.5% −280.0% −2.8% −25.5% 7.4%
Stock pay / revenue 0.4% — 2.1% 11.6% 51.0% — 3.6%
Change in share count 0.0% 3.7% — 5.6% — 55.7% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 68.0% 10.0% 7 of 74
Change in growth rate Growth -574.4pp -0.3pp 74 of 74
Operating margin Profitability -38.9% -5.9% 50 of 67
Net margin Profitability -31.6% -7.3% 55 of 75
Free-cash-flow margin Cash generation 1.4% 10.1% 47 of 74
Stock pay as % of revenue Cash generation 0.4% 3.6% 3 of 69
Change in share count Balance sheet 0.0% 1.5% 21 of 62
Days sales outstanding Balance sheet 37 days 72 days 7 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$97.6M
Institutions reporting
23
Shares held vs prior quarter
▲ 5.0%
Positions opened / closed
5 / 2

Top buyers and sellers, Q2 2026: 11 institutions bought and 9 sold ; the biggest buyer was Trails Edge Capital Partners, LP (+54K shares) and the biggest seller Phoenix Financial Ltd (−65K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Opaleye Management Inc. $37.1M 500K 38.0% 0.0%
Great Point Partners LLC $20.3M 274K 20.8% 0.0%
Phoenix Financial Ltd. $10.8M 146K 11.1% ▼ 30.7%
Trails Edge Capital Partners, LP $10.3M 139K 10.6% ▲ 63.1%
Affinity Asset Advisors, LLC $6.3M 85K 6.5% ▲ 142.6%
Squadron Capital Management LLC $3.9M 52K 4.0% ▲ 67.7%
Citadel Advisors LLC $2.4M 33K 2.5% ▼ 12.4%
Gilder Gagnon Howe & Co LLC $1.7M 23K 1.7% New
Stonepine Capital Management, LLC $1.1M 14K 1.1% ▼ 47.9%
Yelin Lapidot Holdings Management Ltd. $769,870 10K 0.8% ▼ 41.5%
Jane Street Group, LLC $619,588 8K 0.6% ▲ 16.8%
HRT Financial LP $463,000 6K 0.5% ▲ 94.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Sol-gel Technologies Ltd.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $11.2M 49 trades by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $11.2M net buying
Insider Date Trade Shares Price Value
Opaleye Management Inc. 10% owner September 11, 2026 Buy 1,493 $65.95 $98,463
Opaleye Management Inc. 10% owner September 10, 2026 Buy 1,631 $66.80 $108,951
Opaleye Management Inc. 10% owner September 9, 2026 Buy 3,097 $68.71 $212,795
Opaleye Management Inc. 10% owner September 8, 2026 Buy 3,390 $68.74 $233,029
Opaleye Management Inc. 10% owner September 8, 2026 Buy 471 $69.37 $32,673
Opaleye Management Inc. 10% owner September 4, 2026 Buy 2,100 $68.98 $144,858
Opaleye Management Inc. 10% owner September 4, 2026 Buy 918 $69.52 $63,819
Opaleye Management Inc. 10% owner September 2, 2026 Buy 900 $68.95 $62,055
Opaleye Management Inc. 10% owner September 1, 2026 Buy 783 $69.52 $54,434
Opaleye Management Inc. 10% owner August 31, 2026 Buy 217 $69.10 $14,995
Opaleye Management Inc. 10% owner August 31, 2026 Buy 5,000 $68.24 $341,200
Opaleye Management Inc. 10% owner August 28, 2026 Buy 10,000 $71.40 $714,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Sol-gel Technologies Ltd. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Sol-gel Technologies Ltd. in brief

What does Sol-gel Technologies Ltd. do?
Sol-gel Technologies Ltd. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Sol-gel Technologies Ltd.'s stock ticker?
Sol-gel Technologies Ltd. trades under the ticker SLGL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Sol-gel Technologies Ltd.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Sol-gel Technologies Ltd. reported revenue of $19.4M, 68.0% higher than a year earlier, according to its SEC filings.
What is Sol-gel Technologies Ltd.'s free cash flow?
Sol-gel Technologies Ltd.'s free-cash-flow margin is 1.4% of revenue over the trailing twelve months, ranking 47 of the 74 pharmaceuticals companies we cover.
Who are Sol-gel Technologies Ltd.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Opaleye Management Inc., Great Point Partners LLC and Phoenix Financial Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Sol-gel Technologies Ltd.'s market cap?
On December 31, 2025, Sol-gel Technologies Ltd.'s market capitalisation was about $117M and net debt of -$11M. Market figures come from third-party market data and may be delayed.
Who are Sol-gel Technologies Ltd.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Sol-gel Technologies Ltd. are Zhengye Biotechnology Holding Ltd, Jaguar Health, Inc., Verrica Pharmaceuticals Inc., Scilex Holding Co and Sunshine Biopharma Inc. The side-by-side comparison below sets their revenue, margins and growth against Sol-gel Technologies Ltd.'s.
Are insiders buying or selling Sol-gel Technologies Ltd. stock?
Over the last 12 months, Sol-gel Technologies Ltd.'s directors and officers reported 49 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Sol-gel Technologies Ltd.'s next earnings date?
Around November 19, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Sol-gel Technologies Ltd. announces its own schedule.